4.7 Article

Aspiration and swallowing in Parkinson disease and rehabilitation with EMST A randomized trial

Journal

NEUROLOGY
Volume 75, Issue 21, Pages 1912-1919

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181fef115

Keywords

-

Funding

  1. VA Rehab RD [B3721R]
  2. Michael J. Fox Foundation [00056150]
  3. National Parkinson Foundation Center of Excellence
  4. Medtronic, Inc.
  5. NIH [PI R21NS072897, PI R34MH080764, NIDCHD HD046903-01A112/0 [PI]]
  6. University of Florida Foundation
  7. Parkinson Alliance
  8. Michael J. Fox Foundation
  9. National Parkinson Foundation
  10. AstraZeneca
  11. Forest Laboratories, Inc.
  12. Novartis
  13. Solvay Pharmaceuticals, Inc.
  14. Teva Pharmaceutical Industries Ltd.
  15. NIH/NINDS [U10 NS53381-01 [PI]]
  16. Huntington Study Group
  17. Movement Disorders Society
  18. Parkinson Study Group
  19. Society of Progressive Supranuclear Palsy
  20. Merz Pharmaceuticals, LLC
  21. Ipsen
  22. US Veterans Administraion
  23. CurePSP
  24. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service

Ask authors/readers for more resources

Objective: Dysphagia is the main cause of aspiration pneumonia and death in Parkinson disease (PD) with no established restorative behavioral treatment to date. Reduced swallow safety may be related to decreased elevation and excursion of the hyolaryngeal complex. Increased submental muscle force generation has been associated with expiratory muscle strength training (EMST) and subsequent increases in hyolaryngeal complex movement provide a strong rationale for its use as a dysphagia treatment. The current study's objective was to test the treatment outcome of a 4-week device-driven EMST program on swallow safety and define the physiologic mechanisms through measures of swallow timing and hyoid displacement. Methods: This was a randomized, blinded, sham-controlled EMST trial performed at an academic center. Sixty participants with PD completed EMST, 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device. Measures of swallow function including judgments of swallow safety (penetration-aspiration [PA] scale scores), swallow timing, and hyoid movement were made from videofluoroscopic images. Results: No pretreatment group differences existed. The active treatment (EMST) group demonstrated improved swallow safety compared to the sham group as evidenced by improved PA scores. The EMST group demonstrated improvement of hyolaryngeal function during swallowing, findings not evident for the sham group. Conclusions: EMST may be a restorative treatment for dysphagia in those with PD. The mechanism may be explained by improved hyolaryngeal complex movement. Classification of evidence: This intervention study provides Class I evidence that swallow safety as defined by PA score improved post EMST. Neurology (R) 2010;75:1912-1919

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available